BRU •
Healthcare •
Biotechnology •
Quote as of 08/21/2026 17:35
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeBRU
Market Capitalization47,747 mln
Float62.43 mln
Earnings Date10/22/2026
EPS
22.69
Exceptional
P / E
39.73
Overvalued
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-1.71
Likely manipulated
1-Year Forecast
897
Fairly priced
Relative Strength
99
/ 100
Top performer
Business Description
argenx SE is a Netherlands-based biopharmaceutical company focused on treating autoimmune diseases, with operations spanning the United States, Japan, China, and beyond. Its flagship products, VYVGART and VYVGART HYTRULO, are approved treatments for several serious immune conditions, including generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. The company maintains a broad pipeline of experimental therapies targeting a range of autoimmune and inflammatory diseases, supported by key partnerships with companies such as Zai Lab, Halozyme Therapeutics, and AbbVie. Founded in 2008 and headquartered in Amsterdam, argenx has grown from a research-stage venture into a commercially active global business.
